Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer

ABT‐751 is an orally bioavailable sulfonamide with antimitotic properties. A nonrandomized phase 1 dose‐escalation study of ABT‐751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose‐limiting toxicity (DLT), and pharmacok...

詳細記述

保存先:
書誌詳細
出版年:J Clin Pharmacol
主要な著者: Rudek, Michelle A., Dasari, Arvind, Laheru, Daniel, He, Ping, Jin, Runyan, Walker, Rosalind, Taylor, Gretchen E., Jimeno, Antonio, Donehower, Ross C., Hidalgo, Manuel, Messersmith, Wells A., Purcell, W. Thomas
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2016
主題:
Therapeutics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4892995/
https://ncbi.nlm.nih.gov/pubmed/26632033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.681
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料